Bausch Health to Buy Durect for $1.75 Per Share in All-Cash Deal

Bausch Health will indirectly acquire Durect Corporation for $1.75 per share in an all-cash transaction.

• Upfront consideration of about $63 million at closing
• Two potential additional net sales sales milestone payments of up to $350 million in the aggregate
• Deal includes a novel therapeutic molecule, larsucosterol
• Premium of approximately 191% to the 30-day volume-weighted average trading price of Durect’s common stock ended on July 28
• The transaction is expected to close in 3Q 2025
• Assuming the closing of the tender offer, Bausch Health will acquire any Durect shares not tendered into the tender offer through a merger of a wholly ...